Clinical trial updates in myeloma: anti-CD38 mAbs, ADCs, treating smoldering myeloma & more

0 Views

  • Thanks! Share it with your friends!

    You disliked this video. Thanks for the feedback!

admin
Published
In this discussion, Rafael Fonseca, MD, Mayo Clinic, Phoenix, AZ, Ola Landgren, MD, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, Thomas Martin, MD, University of California San Francisco, San Francisco, CA, and Adriana Rossi, MD, Mount Sinai, New York City, NY, share updates with the use of several agents in multiple myeloma. First, Dr Martin shares updates with the use of anti-CD38 monoclonal antibodies (mAbs), including daratumumab and isatuximab. Following this, Dr Rossi discusses updates on the use of antibody-drug conjugates (ADCs) and bispecific antibodies. Dr Landgren then shares his thoughts on the treatment of smoldering myeloma and further comments on how measurable residual disease (MRD) may be used in clinical decision-making. This session was filmed at the 18th International Workshop on Multiple Myeloma (iwMyeloma), held in Miami, FL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Category
Oncology
Be the first to comment

Up Next